How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?

Charalabos-Markos Dintsios · Nadja Chernyak

Accepted: 5 December 2021 / Published online: 29 December 2021
© The Author(s) 2021

1 Institute for Health Services Research and Health Economics, Medical Faculty, Heinrich Heine University, Building 17.11, Moorenstr. 5, 40225 Düsseldorf, Germany

1 Value-Based Pricing (VBP)

In pricing policy, the 3-C’s model for pricing strategy is referred to as cost-based, competitor-based, and customer-based pricing, whereby the former can be defined as a profit mark-up on costs, the second as positioning in relation to competitors, and the latter as the value of specific benefit attributes from the customer’s point of view (otherwise ‘value-based pricing’ (VBP)) [1]. There is a broad consensus that pricing based on value from the customer’s perspective and their willingness to pay can positively influence a company’s pricing power in terms of higher pricing compared with the other two Cs [2].

Value-based pricing for pharmaceuticals was not a German novelty and has already being pursued in some European healthcare systems [3, 4] and is currently being introduced in Japan, the second largest pharmaceutical market worldwide [5]. However, both criteria and measurement of the value of drugs can differ relatively widely depending on the healthcare system or stakeholder perspective [6, 7]. Its theoretical origins for health services can be found in the well-known Harvard competitive strategist Porter [8, 9], and in pharmaceutical supply, its precursor can be seen in Sweden after 2002 at a time when the term was not yet broadly used [10].

2 Paradigm Shift

In their reflections on the changing face of German pharmaceutical policy, Gerber, Stock, and Dintsios [11] asked 10 years ago how far Germany was from VBP after introducing the ‘Act to Reorganize the Pharmaceuticals’ Market in the Statutory Health Insurance System’ (AMNOG) [12], which came into effect in 2011, leaving the question somewhat open. Synoptically, the AMNOG can be described as a regulation that aims for VBP via the preceding appraisal by the decision-making federal joint committee (G-BA) based on the assessment of the available study evidence by its contract institute, the Institute for Quality and Efficiency in Health Care. This appraisal serves for achieving a time-shifted reimbursement amount subsequent of the market launch of new drugs with free pricing for 1 year on the basis of negotiations with the National Association of Statutory Health Insurance Funds (GKV-SV). As the GKV-SV is negotiating new drug reimbursement amounts also for private insurance schemes, it acts as a monopsonist, being at the same time a constituent stakeholder of the G-BA (Fig. 1). Conversely, this means that the manufacturer will pursue the cost-based or competition-based pricing strategy, whereby they can achieve a temporary monopoly position through the time-limited patent protection for genuine drug innovations within the framework of free pricing. Under the AMNOG, however, the latter only applies for the first 12 months after market entry, as mentioned above.

3 Expectations on VBP

Gerber et al. [11] stated that as there is no way to determine an appropriate maximum reimbursable amount on the basis of the submitted dossier for the benefit assessment of new drugs by the manufacturer, it will become rather difficult to balance protection of statutory insured from unsubstantiated costs for new drugs and rightful claims of a manufacturer
that launches a real innovative drug with a relevant difference in benefit. Subsequently, they concluded that as the premium for new drugs should depend on their level of benefit vs current standards under VBP principles, it seemed that Germany had taken an indeterminate step with the AMNOG towards VBP. Ten years later, a conclusive answer can be given to the question on how far Germany is from VBP.

Because in the context of German drug pricing GKV-SV acts as a demand side for patients consuming healthcare products and using services, representing the interests of its insured and not explicitly that of the patients, in terms of the AMNOG, VBP can be seen as an ex-post pricing by determining the value added of an offer for the GKV-SV or by empirically determining the willingness to pay of the GKV-SV and thus stipulating the resulting profit contribution for the manufacturer.

4 Implementation of VBP

As depicted in Fig. 1, after the appraisal of new drugs by the G-BA, price negotiations between the GKV-SV and the manufacturer on the reimbursement amount begin. These negotiations are based on the framework agreement, signed by the GKV-SV and the relevant pharmaceutical companies’ unions [13]. The main points to consider within the negotiations according to the framework agreement are: (1) the annual therapy costs of the comparator, (2) the extent of the added benefit, (3) comparable pharmaceuticals within the authorized indication(s) of the new drug, and (4) European prices in the referenced countries adjusted at purchase power parity and weighted by the respective sales volumes. The European countries, which are looked at while comparing the prices, are included in a specific basket that includes the following countries: Belgium, Denmark, Finland, France, Greece, UK, Ireland, Italy, the Netherlands, Austria, Portugal, Sweden, Slovakia, Spain, and the Czech Republic. The choice of countries was based on three criteria: (1) countries from all states of the European Economic Area, (2) countries with an additive population of 80% of the European Economic Area (excluding Germany), and (3) countries with a similar economic performance compared to Germany. The framework agreement clarifies that the negotiations follow a premium pricing philosophy in the sense of a mark-up calculation on the annual cost of the comparator. Furthermore, the reimbursement amounts are derived by considering every subpopulation particularly [14, 15]. Drugs that are not granted an added benefit are assigned to a reference price group if available or priced with the price of the comparator as an upper limit. If no agreement is reached, an arbitration board is called [16].

5 Not an Ideal-Typical VBP

Following the taxonomy of Sussex et al. [17], AMNOG is to be assigned to the VBP approach in the broader sense and, according to Jommi et al. [3], it fulfills the criterion of taking
into account the value of a new drug (additional benefit) as well as the second-order condition of taking into account the budget impact. However, apart from descriptive information on the envisaged regulations regarding drug price negotiations, little is known from the international literature about their actual implementation [3]. If one takes a closer look at the framework agreement, it becomes evident that, in addition to VBP per se, elements of internal reference pricing by considering the prices of comparable drugs in the indication of interest and external reference pricing (ERP) [18] via the European prices are implemented as well. For the positive and negative effects of ERP on drug spending and supply and a comparison of the short-term and long-term effects of VBP and ERP, see Kanavos et al. [19, 20]. In practice, there is enough evidence that next to VBP, internal reference pricing and ERP is implemented as well in the negotiations of the manufacturers with the GKV-SV [21] or the decisions of the arbitration board [16].

6 Impact of VBP in a Monopsonistic Pharmaceutical Market

As the first aim of AMNOG was cost containment, the expectation of an increased pricing power for manufacturers by VBP [2] has simply turned to the opposite as they have to negotiate with a monopsonistic purchaser (GKV-SV). The cost-containment target pursued with the AMNOG (Eur 2 billion [22]) was not achieved until 2018, 7 years after the law was passed, with savings of EUR 2.65 billion [23].

It is well known from the standard microeconomic literature [24] that for monopsonists, marginal expenditure is higher than average expenditure, which means that equating marginal value with marginal expenditure as a function of supply elasticity results in lower quantities at lower prices compared with the competitive market. Monopsony power leads to net welfare losses, as the level of output moves below the competitive level or, in other words, consumers with a willingness to pay higher than the marginal cost of production are denied access [25]. Faced with the dilemma of a guaranteed equilibrium quantity of the competitive market at a lower price or no purchase at all of new drugs according to the ‘all or nothing’ model in a monopsonistic pharmaceutical market [26], producers will not reduce the equilibrium quantity, at least in the short run. This is mainly because producers in order to survive in the market will reduce their prices until their producer surplus is completely depleted. This may even lead to lower prices than in the monopsony without an ‘all or nothing’ supply, with innovative producers with higher average costs exiting the market in the long run, as it has been already the case with some market withdrawals of drugs in Germany after the introduction of AMNOG [27]. From this behavior of the (absolute) monopsonist, reduced and delayed introductions of drug innovations are postulated despite a temporary monopoly position owing to time-limited patent protection [28]. Although the creation of countervailing market power through a bilateral monopoly or a monopsony monopoly market can lead to a Pareto optimum as under full competition [29], such a pharmaceutical market cannot be organized because of substitutional competition (relative monopolies). Empirically, Danzon [30] was able to show for the European Union that drug prices are far away from optimal Ramsey prices, i.e., a second-best solution for regulating natural monopolies via mark-ups on marginal cost prices calculated inversely proportional to price elasticity for the best possible allocative efficiency due to parallel trade and monopsonistic market structures. Finally, we can conclude that Germany is close to VBP, but the features of VBP in the German pharmaceutical market are definitely not compatible with the expected ones from the 3-C’s model for pricing strategy.

Declarations

Funding Open Access funding enabled and organized by Projekt-DEAL.

Conflict of interest CMD is next to his academic affiliation employed by Bayer Vital GmbH, Leverkusen, Germany. NC has no conflicts of interests or competing interests to declare.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Hinterhuber A. Towards value-based pricing: an integrative framework for decision making. Ind Mark Manage. 2004;33(8):765–78.
2. Liozu SM. Value-based pricing special issue: editorial. J Rev Pricing Manage. 2017;16(1):1–3.
3. Jommi C, Armeni P, Costa F, Bertolani A, Otto M. Implementation of value-based pricing for medicines. Clin Ther. 2020;42(1):15–24.
4. Prieto-Pinto L, Garzón-Orjuela N, Lasalvia P, Castañeda-Cardona C, Rosselli D. International experience in therapeutic value and value-based pricing: a rapid review of the literature. Value Health Reg Issues. 2020;23:37–48.
5. Shiroiwa T. Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan. Int J Technol Assess Health Care. 2020;36(3):270–6.

6. Towse A, Barnsley P. Approaches to identifying, measuring, and aggregating elements of value. Int J Technol Assess Health Care. 2013;29(4):360–4.

7. Vermeulen KM, Krabbe PFM. Value judgment of health interventions from different perspectives: arguments and criteria. Cost Eff Resour Alloc. 2018;16:16.

8. Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81.

9. Porter ME, Teisberg EO. Redefining health care: creating value-based competition on results. Boston: Harvard Business School Press; 2006.

10. Moïse P, Docteur E. Pharmaceutical pricing and reimbursement policies in Sweden. Paris: OECD; 2007.

11. Gerber A, Stock S, Dintsios CM. Reflections on the changing face of German pharmacetical policy: how far is Germany from value-based pricing? Pharmacoeconomics. 2011;29(7):549–53.

12. AMNOG. Act to reorganize the pharmaceuticals’ market in the SHI system (Arzneimittelneuordnungsgesetz-AMNOG). BGBl2010; 2010. pp. 2262–77.

13. GKV-SV. Bundesverband der Arzneimittel-Hersteller e.V., Bundesverband der Pharmazeutischen Industrie e.V., Pro Generika e.V., Verband Forschender Arzneimittelhersteller e.V. In: Framework agreement according to §130b (9) Social Code V. 2016.

14. Rasch A, Dintsios CM. Subgroups in the early benefit assessment of pharmaceuticals: a methodical review. Z Evid Fortbild Qual Gesundwes. 2015;109(1):69–78.

15. Ruof J, Dintsios CM, Schwartz FW. Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach. Value Health. 2014;17(4):307–9.

16. Ludwig S, Dintsios CM. Arbitration board setting reimbursement amounts for pharmaceutical innovations in Germany when price negations between payers and manufacturers fail: an empirical analysis of 5 years’ experience. Value Health. 2016;19(8):1016–25.

17. Sussex J, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013;31(1):1–10.

18. Rémuzat C, Urbinati D, Mzoughi O, El-Hammi E, Belgaied W, Touni M. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;2015:3.

19. Kanavos P, Fontrier A-M, Gill J, Ethymiadiou O. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Health Econ. 2020;21(1):129–51.

20. Kanavos P, Nicod E, Espin J, Aardw S. Short- and long-term effects of value-based pricing vs. external price referencing. London: LSE; 2010.

21. Gandjour A, Schüßler S, Hammerschmidt T, Dintsios CM. Predictors of negotiated prices for new drugs in Germany. Eur J Health Econ. 2020;21(7):1049–57.

22. Deutscher Bundestag. [Entwurf eines Gesetzes zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarkteuordnungsgesetz—AMNOG)]; 2010.

23. Schwabe U, Ludwig W-D. Arzneiverordnungen 2019 im Überblick. In: Schwabe U, Ludwig W-D, editors. Arzneiverordnungserhebung 2020. Berlin, Heidelberg: Springer, Berlin Heidelberg; 2020. pp. 3–41.

24. Pindyck RS, Rubinfeld DL. Microeconomics, 9th ed. Pearson, New York; 2018.

25. Pauly MV. Market power, monopsony, and health insurance markets. J Health Econ. 1988;7(2):111–28.

26. Herndon JB. Health insurer monopsony power: the all-or-none model. J Health Econ. 2002;21(2):197–206.

27. Staab TR, Walter M, Mariotti NS, Dintsios CM, Graf-von-der-Schulenburg JM, Amelung VE, et al. Market withdrawals of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ Rev. 2018;8(1):23.

28. Bungenstock JM. Innovative Arzneimittel in der gesetzlichen Krankenversicherung: eine normativ-ökonomische Analyse zu Versorgung und Finanzierung. 1st ed. Baden-Baden: Nomos Verlagsgesellschaft mbH & Co. KG; 2011.

29. Fritsch M. Marktversagen und Wirtschaftspolitik: mikroökonomische Grundlagen staatlichen Handelns. 9th ed. München: C.H.Beck; 2014.

30. Danzon PM. Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int J Econ Business. 1997;4(3):301–22.